205 related articles for article (PubMed ID: 31545404)
1. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
3. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
Kim WT; Yun SJ; Yan C; Jeong P; Kim YH; Lee IS; Kang HW; Park S; Moon SK; Choi YH; Choi YD; Kim IY; Kim J; Kim WJ
Yonsei Med J; 2016 Jul; 57(4):865-71. PubMed ID: 27189278
[TBL] [Abstract][Full Text] [Related]
5. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
6. Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.
Pereira F; Domingues MR; Vitorino R; Guerra IMS; Santos LL; Ferreira JA; Ferreira R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542319
[TBL] [Abstract][Full Text] [Related]
7. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
[TBL] [Abstract][Full Text] [Related]
8. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.
Sahu D; Lotan Y; Wittmann B; Neri B; Hansel DE
Cancer Med; 2017 Sep; 6(9):2106-2120. PubMed ID: 28766915
[TBL] [Abstract][Full Text] [Related]
9. Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review.
Cho MH; Kim SH; Park WS; Joung JY; Seo HK; Chung J; Lee KH
World J Surg Oncol; 2016 Oct; 14(1):270. PubMed ID: 27765044
[TBL] [Abstract][Full Text] [Related]
10. Recognition of early and late stages of bladder cancer using metabolites and machine learning.
Kouznetsova VL; Kim E; Romm EL; Zhu A; Tsigelny IF
Metabolomics; 2019 Jun; 15(7):94. PubMed ID: 31222577
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells.
Fujimura Y; Ikenaga N; Ohuchida K; Setoyama D; Irie M; Miura D; Wariishi H; Murata M; Mizumoto K; Hashizume M; Tanaka M
Pancreas; 2014 Mar; 43(2):311-8. PubMed ID: 24518513
[TBL] [Abstract][Full Text] [Related]
12. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Yang Z; Fu B; Zhou L; Xu J; Hao P; Fang Z
BMC Urol; 2019 Jul; 19(1):69. PubMed ID: 31340801
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression.
Putluri N; Shojaie A; Vasu VT; Vareed SK; Nalluri S; Putluri V; Thangjam GS; Panzitt K; Tallman CT; Butler C; Sana TR; Fischer SM; Sica G; Brat DJ; Shi H; Palapattu GS; Lotan Y; Weizer AZ; Terris MK; Shariat SF; Michailidis G; Sreekumar A
Cancer Res; 2011 Dec; 71(24):7376-86. PubMed ID: 21990318
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
Jin JO; Lehmann J; Taxy J; Huo D; Stöckle M; Vogelzang NJ; Steinberg G; Stadler WM
Clin Genitourin Cancer; 2006 Sep; 5(2):150-4. PubMed ID: 17026804
[TBL] [Abstract][Full Text] [Related]
16. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
[TBL] [Abstract][Full Text] [Related]
17. Discovering biomarkers in bladder cancer by metabolomics.
Zhang WT; Zhang ZW; Guo YD; Wang LS; Mao SY; Zhang JF; Liu MN; Yao XD
Biomark Med; 2018 Dec; 12(12):1347-1359. PubMed ID: 30507300
[TBL] [Abstract][Full Text] [Related]
18. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
[TBL] [Abstract][Full Text] [Related]
20. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
